Compare Stocks: CTOR, CCCC, ARTV, and PRLD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$6.99 -6.7%	$10.44	$2.71 ▼ $14.53	$341.74M	2.18	439,757 shs	507,050 shs
CCCC C4 Therapeutics	$2.98 -1.7%	$3.69	$1.69 ▼ $5.17	$366.62M	2.94	1.90 million shs	2.12 million shs
CTOR Citius Oncology	$1.05	$0.79	$0.49 ▼ $2.25	$97.63M	3.52	94,431 shs	26,668 shs
PRLD Prelude Therapeutics	$3.88 -2.8%	$5.03	$1.15 ▼ $6.83	$309.24M	0.97	498,941 shs	336,078 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	0.00%	-18.82%	-41.46%	-27.34%	+142.71%
CCCC C4 Therapeutics	0.00%	-12.09%	-27.32%	-30.05%	+23.14%
CTOR Citius Oncology	0.00%	-7.89%	+32.86%	+67.73%	-41.99%
PRLD Prelude Therapeutics	0.00%	-20.33%	-38.80%	-11.42%	+231.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$6.99 -6.7%	$10.44	$2.71 ▼ $14.53	$341.74M	2.18	439,757 shs	507,050 shs
CCCC C4 Therapeutics	$2.98 -1.7%	$3.69	$1.69 ▼ $5.17	$366.62M	2.94	1.90 million shs	2.12 million shs
CTOR Citius Oncology	$1.05	$0.79	$0.49 ▼ $2.25	$97.63M	3.52	94,431 shs	26,668 shs
PRLD Prelude Therapeutics	$3.88 -2.8%	$5.03	$1.15 ▼ $6.83	$309.24M	0.97	498,941 shs	336,078 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	0.00%	-18.82%	-41.46%	-27.34%	+142.71%
CCCC C4 Therapeutics	0.00%	-12.09%	-27.32%	-30.05%	+23.14%
CTOR Citius Oncology	0.00%	-7.89%	+32.86%	+67.73%	-41.99%
PRLD Prelude Therapeutics	0.00%	-20.33%	-38.80%	-11.42%	+231.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	2.83	Moderate Buy	$39.00	457.94% Upside
CCCC C4 Therapeutics	2.33	Hold	$7.00	134.90% Upside
CTOR Citius Oncology	1.00	Sell	N/A	N/A
PRLD Prelude Therapeutics	2.50	Moderate Buy	$8.75	125.52% Upside

Current Analyst Ratings Breakdown

Latest CTOR, CCCC, ARTV, and PRLD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	PRLD Prelude Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
9/16/2026	CTOR Citius Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/31/2026	CTOR Citius Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	PRLD Prelude Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/29/2026	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/28/2026	CTOR Citius Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	ARTV Artiva Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CCCC C4 Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/14/2026	CTOR Citius Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/30/2026	CTOR Citius Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	$4.48 per share	N/A
CCCC C4 Therapeutics	$35.04M	10.46	N/A	N/A	$2.65 per share	1.12
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.54 per share	N/A
PRLD Prelude Therapeutics	$22.42M	13.81	N/A	N/A	$1.09 per share	3.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	-$83.86M	-$3.30	N/A	N/A	N/A	N/A	-53.86%	-48.16%	11/11/2026 (Estimated)
CCCC C4 Therapeutics	-$104.99M	-$1.00	N/A	N/A	N/A	-289.44%	-45.45%	-30.90%	11/5/2026 (Estimated)
CTOR Citius Oncology	-$24.76M	-$0.47	N/A	N/A	N/A	N/A	-102.98%	-43.49%	N/A
PRLD Prelude Therapeutics	-$99.50M	-$0.73	N/A	N/A	N/A	N/A	-75.35%	-44.39%	11/11/2026 (Estimated)

Latest CTOR, CCCC, ARTV, and PRLD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	CTOR Citius Oncology	-$0.07	-$0.08	-$0.01	-$0.08	$2.50 million	$1.49 million
8/11/2026	Q2 2026	CCCC C4 Therapeutics	-$0.2264	-$0.18	+$0.0464	-$0.18	$4.00 million	$6.64 million
8/11/2026	Q2 2026	PRLD Prelude Therapeutics	-$0.1967	-$0.14	+$0.0567	-$0.14	$5.70 million	$5.70 million
8/6/2026	Q2 2026	ARTV Artiva Biotherapeutics	-$0.6251	-$0.63	-$0.0049	-$0.63	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	24.16	24.16
CCCC C4 Therapeutics	N/A	5.45	5.45
CTOR Citius Oncology	0.25	0.73	0.34
PRLD Prelude Therapeutics	N/A	4.07	4.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
CCCC C4 Therapeutics	78.81%
CTOR Citius Oncology	70.52%
PRLD Prelude Therapeutics	79.72%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	1.80%
CCCC C4 Therapeutics	5.60%
CTOR Citius Oncology	9.82%
PRLD Prelude Therapeutics	49.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	115	48.89 million	48.01 million	N/A
CCCC C4 Therapeutics	104	123.03 million	116.14 million	Optionable
CTOR Citius Oncology	N/A	92.98 million	83.85 million	N/A
PRLD Prelude Therapeutics	79	79.80 million	40.54 million	Optionable

CTOR, CCCC, ARTV, and PRLD Headlines

Recent News About These Companies

Prelude Therapeutics stock gains as FDA clears new breast cancer drug trial

September 21, 2026 | ad-hoc-news.deA

Prelude Therapeutics (NASDAQ:PRLD) Coverage Initiated at JPMorgan Chase & Co.

September 19, 2026 | americanbankingnews.com

Prelude Therapeutics (NASDAQ:PRLD) Stock Rating Lowered by Wall Street Zen

September 19, 2026 | marketbeat.com

JPMorgan Chase & Co. Initiates Coverage on Prelude Therapeutics (NASDAQ:PRLD)

September 17, 2026 | marketbeat.com

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 11, 2026 | globenewswire.com

Prelude Therapeutics, Incorporated: Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A ...

September 10, 2026 | finanznachrichten.de

Prelude Therapeutics Receives FDA Clearance For PRT13722 IND In HR+/HER2-Breast Cancer

September 10, 2026 | rttnews.com

Prelude Therapeutics Cleared by FDA for Phase 1 Breast Cancer Drug Trial

September 10, 2026 | finance.yahoo.com

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

September 10, 2026 | globenewswire.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Given Average Rating of "Hold" by Brokerages

September 6, 2026 | marketbeat.com

Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Buy at Wall Street Zen

September 6, 2026 | marketbeat.com

BlackRock Inc. Acquires Shares of 1,797,501 Prelude Therapeutics Incorporated $PRLD

September 5, 2026 | marketbeat.com

Wall Street Zen Downgrades Prelude Therapeutics (NASDAQ:PRLD) to Hold

August 29, 2026 | marketbeat.com

Prelude Therapeutics: A Prognosis After Year-Long Rally

August 23, 2026 | seekingalpha.com

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | markets.businessinsider.com

Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

July 31, 2026 | zacks.com

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why

July 17, 2026 | zacks.com

Prelude Therapeutics

July 14, 2026 | fool.com

Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 10, 2026 | seekingalpha.com

Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

May 16, 2026 | finance.yahoo.com

Prelude Therapeutics (PRLD) price target increased by 11.49% to 7.01

May 14, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CTOR, CCCC, ARTV, and PRLD Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$6.99 -0.50 (-6.68%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$6.98 0.00 (-0.07%)

As of 09/25/2026 07:30 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

C4 Therapeutics NASDAQ:CCCC

$2.98 -0.05 (-1.65%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$3.02 +0.04 (+1.17%)

As of 09/25/2026 07:51 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Citius Oncology NASDAQ:CTOR

$1.05 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$1.05 0.00 (0.00%)

As of 09/25/2026 04:10 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Prelude Therapeutics NASDAQ:PRLD

$3.88 -0.11 (-2.76%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$4.08 +0.20 (+5.03%)

As of 09/25/2026 07:30 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTOR, CCCC, ARTV, and PRLD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTOR, CCCC, ARTV, and PRLD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTOR, CCCC, ARTV, and PRLD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CTOR, CCCC, ARTV, and PRLD Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

C4 Therapeutics NASDAQ:CCCC

Citius Oncology NASDAQ:CTOR

Prelude Therapeutics NASDAQ:PRLD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTOR, CCCC, ARTV, and PRLD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTOR, CCCC, ARTV, and PRLD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTOR, CCCC, ARTV, and PRLD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CTOR, CCCC, ARTV, and PRLD Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

C4 Therapeutics NASDAQ:CCCC

Citius Oncology NASDAQ:CTOR

Prelude Therapeutics NASDAQ:PRLD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools